SpringWorks Therapeutics Announces Full Enrollment of Phase 3 DeFi Trial Evaluating Nirogacestat in Adult Patients with Desmoid Tumors


You May Also Like

Pluristem Reports Third Quarter Fiscal 2018 Corporate and Financial Highlights

HAIFA, Israel, May 10, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a ...

Oncology Venture enters into financing agreement

Company AnnouncementOncology Venture A/S enters into a financing agreement based on the issuance of ...